HC Wainwright Weighs in on Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Krystal Biotech in a research note issued on Wednesday, February 18th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of $1.30 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $310.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Several other research analysts have also issued reports on KRYS. Bank of America raised their price target on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Citigroup raised their target price on Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a report on Wednesday. Chardan Capital upped their price target on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Research lowered shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Finally, Jefferies Financial Group upped their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $318.75.

Krystal Biotech Stock Performance

KRYS opened at $261.80 on Thursday. The company has a fifty day moving average price of $265.50 and a two-hundred day moving average price of $209.66. The firm has a market capitalization of $7.65 billion, a PE ratio of 38.22 and a beta of 0.49. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The firm had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of the business. Greenline Wealth Management LLC bought a new stake in Krystal Biotech in the fourth quarter valued at approximately $34,000. Sound Income Strategies LLC boosted its position in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares during the period. UMB Bank n.a. boosted its position in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the period. Bessemer Group Inc. increased its holdings in shares of Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares during the last quarter. Finally, Global Retirement Partners LLC raised its position in shares of Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after purchasing an additional 142 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the transaction, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the sale, the chief accounting officer directly owned 19,318 shares in the company, valued at $5,257,200.52. This represents a 39.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 13.70% of the company’s stock.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: KRYS reported a quarterly earnings beat (Feb. 17) — EPS and revenue topped consensus, which drove an initial gap up in shares after the print. That strong operational result supports higher near-term momentum for the stock. Krystal Biotech Shares Gap Up After Earnings Beat
• Positive Sentiment: Chardan Capital raised its price target to $323, signaling continued institutional enthusiasm from some brokers and providing upside narrative against the recent pullback. Chardan Boosts KRYS Price Target to $323
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $310 target, indicating that at least one major analyst house still views medium-term upside despite model revisions. HC Wainwright Coverage
• Neutral Sentiment: Analyst commentary pieces are reframing KRYS after recent data and target resets — these articles summarize shifting expectations around the Vyjuvek commercial ramp and pipeline positioning, useful context but not direct catalysts. Why Analysts See KRYS Story Shifting Reassessing KRYS After Rally and Pipeline Focus
• Neutral Sentiment: Reported short-interest figures appear to be erroneous/zero (entries show 0 shares and 0.0 days-to-cover). Because the data is clearly inconsistent, it is unlikely to be a reliable trading signal today.
• Negative Sentiment: HC Wainwright materially trimmed EPS forecasts across FY2026–FY2028 (e.g., FY2026 cut from ~$7.41 to $5.78 and FY2027 from ~$10.21 to $6.52), reducing modeled growth and future earnings upside — a clear negative for valuation expectations even though the firm kept its Buy rating. HC Wainwright Estimates and Revisions

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.